# 抗感染剂市场

> 抗感染剂市场研究报告按产品类型（抗生素、抗病毒药物、抗真菌药物、抗寄生虫药物、其他）、按应用（医院、诊所、药店、居家医疗、其他）、按最终用户（个人、医院、诊所、药店、其他）以及按地区（北美、欧洲、南美、亚太、中东和非洲）- 预测到2035年

- **Forecast Period:** 2025 - 2035
- **CAGR:** 4.82%
- **2024:** $ 59.96 Billion
- **2025:** $ 62.85 Billion
- **2035:** $ 100.66 Billion
- **Key Players:** Pfizer (US), Merck & Co (US), Johnson & Johnson (US), Novartis (CH), GSK (GB), AstraZeneca (GB), Bayer (DE), AbbVie (US), Sanofi (FR)

**Report ID:** MRFR/HC/27129-HCR · **Pages:** 128 · **Author:** Rahul Gotadki · **Last Updated:** April 06, 2026

**URL:** https://www.marketresearchfuture.com/reports/anti-infective-agent-market-28826

---

## Market Summary

## **Anti-infective Agent Market Overview**

As per MRFR analysis, the Anti-infective Agent Market Size was estimated at 59.96 (USD Billion) in 2024. The Anti-infective Agent Market Industry is expected to grow from 62.85 (USD Billion) in 2025 to 96.03 (USD Billion) till 2034, at a CAGR (growth rate) is expected to be around 4.82% during the forecast period (2025 - 2034).

### **Key Anti-infective Agent Market Trends Highlighted**

The increasing prevalence of infectious diseases and the emergence of antibiotic-resistant strains are driving the growth of the anti-infective agent’s market. The demand for new and innovative treatments is being fueled by the spread of multi-drug-resistant bacteria and the need to combat emerging infectious diseases.

Moreover, the rising awareness of infection prevention and control measures, along with the growing adoption of antimicrobial stewardshipprograms, are contributing to the market growth.****

Source: Primary Research, Secondary Research, MRFR Database and Analyst Review

Key market drivers include the increasing prevalence of hospital-acquired infections and the rising incidence of antibiotic resistance. Opportunities for growth lie in the development of new and innovative therapeutic approaches, such as targeted therapies and combination therapies.

Recent trends in the market include the increasing focus on precision medicine and the growing adoption of personalized treatment strategies.

## **Anti-infective Agent Market Drivers**

### Increasing Prevalence of Infectious Diseases

The rising incidence of infectious diseases, including bacterial, viral, and fungal infections, is a primary driver of growth in the Anti-infective Agent Market.

Factors such as the emergence of antibiotic-resistant bacteria, increased global travel, and the spread of infectious diseases through contaminated food and water contribute to this trend.

The increasing prevalence of chronic diseases, such as HIV/AIDS and cancer, which weaken the immune system and make individuals more susceptible to infections, further fuels market growth.

### Growing Demand for Advanced Anti-Infective Therapies

The development of new and more effective anti-infective agents is another key driver of market growth. Pharmaceutical companies are investing heavily in research and development to create novel therapies that can combat resistant infections and provide better patient outcomes.

The increasing demand for targeted therapies, personalized medicine, and combination therapies to enhance efficacy and reduce side effects is driving the market.

Technological Advancements and Personalized Medicine

Technological advancements, such as advancements in genomics and molecular diagnostics, are revolutionizing the Anti-infective Agent Market.

These advancements enable the identification of specific pathogens, tailoring therapies to individual patient profiles, and monitoring treatment responses more effectively.

The development of rapid diagnostic tests, point-of-care devices, and personalized treatment approaches are contributing to the growth of the market.

## **Anti-infective Agent Market Segment Insights**

### **Anti-infective Agent Market Product Type Insights**

The Anti-infective Agent Market is segmented by Product Type into Antibiotics, Antivirals, Antifungals, Antiparasitics, and Others. Among these segments, Antibiotics held the largest market share in 2023 and is expected to continue its dominance throughout the forecast period.

The growth of this segment can be attributed to the increasing prevalence of bacterial infections and the rising demand for antibiotics to treat these infections. Antivirals are expected to witness significant growth over the forecast period, owing to the rising incidence of viral infections such as influenza, HIV, and hepatitis.

Antifungals are also expected to experience steady growth, driven by the increasing prevalence of fungal infections, particularly among immunocompromised individuals. Antiparasitics are expected to account for a relatively smaller share of the Anti-infective Agent Market, but they are expected to grow at a steady pace, driven by the rising prevalence of parasitic infections in developing countries.

The Others segment includes a variety of anti-infective agents, such as antitubercular drugs and antiprotozoal drugs. This segment is expected to grow at a moderate pace over the forecast period.

Overall, the Anti-infective Agent Market is expected to exhibit steady growth over the forecast period, driven by the increasing prevalence of infections and the rising demand for effective anti-infective agents.

Source: Primary Research, Secondary Research, _Market Research Future_ Database and Analyst Review

### **Anti-infective Agent Market Application Insights**

The application segment of the Anti-infective Agent Market plays a crucial role in shaping the market landscape. Hospitals dominate the market, accounting for a significant share of the revenue due to the high volume of patients seeking treatment for infectious diseases and the availability of advanced medical facilities.

Clinics, with their convenient locations and accessibility, cater to a substantial portion of the market, particularly for minor infections and routine check-ups. Pharmacies serve as essential distribution channels for anti-infective agents, offering both prescription and over-the-counter medications, contributing to a notable share of the market revenue.

Home healthcare, driven by the growing demand for remote patient monitoring and chronic disease management, is expected to witness significant growth in the coming years. Other applications, including long-term care facilities and veterinary medicine, also contribute to the overall market size.

### **Anti-infective Agent Market End User Insights**

The End User segment of the Anti-infective Agent Market is comprised of various entities that utilize these agents for the treatment and prevention of infectious diseases. Key end users include Individuals: Individuals self-administer anti-infective agents, primarily through over-the-counter purchases for minor infections.

In 2023, the market for anti-infective agents among individuals was valued at USD 12.3 billion, driven by rising awareness of self-care and the increasing prevalence of minor infections. Hospitals: Hospitals are major consumers of anti-infective agents due to the high incidence of infections among hospitalized patients.

In 2023, hospitals accounted for approximately 45% of the Anti-infective Agent Market revenue, with a market value of USD 24.7 billion. This is attributed to the widespread use of antibiotics, antifungals, and antivirals for treating infections acquired in hospital settings.

Clinics: Clinics, including outpatient clinics and specialized clinics, contribute significantly to the demand for anti-infective agents. In 2023, the market value for anti-infective agents in clinics was estimated at USD 10.2 billion. This is driven by the increasing number of clinic visits and the growing prevalence of infectious diseases in ambulatory settings.

Pharmacies: Pharmacies serve as a primary distribution channel for anti-infective agents, both over the counter and prescription-based. In 2023, the pharmacy segment held a market share of approximately 18%, with a market value of USD 9.8 billion.

The growth of online pharmacies and the convenience of home delivery are contributing to the increasing demand for anti-infective agents through pharmacies.

Others: This category includes various end users such as nursing homes, long-term care facilities, and veterinary clinics. The market for anti-infective agents in this segment is expected to grow steadily in the coming years due to the increasing geriatric population and rising pet ownership.

### **Anti-infective Agent Market Regional Insights**

The Anti-infective Agent Market size was valued at USD 50.9 billion in 2023, and it is expected to reach USD 77.37 billion by 2032, witnessing a CAGR of 4.8% from 2025 to 2034. Regionally, North America is expected to hold the largest market share of 38.5% in 2023.

This is attributed to the presence of a large number of pharmaceutical companies, well-established healthcare infrastructure, and high healthcare expenditure in the region. Europe is expected to be the second-largest market, with a market share of 31.2% in 2023.

The increasing prevalence of infectious diseases and the growing demand for effective anti-infective agents are driving the growth of the market in this region.

APAC is expected to be the fastest-growing region, with a CAGR of 5.5% from 2025 to 2034. This growth is attributed to the rising healthcare expenditure, increasing population, and growing awareness of infectious diseases in the region. South America and MEA are expected to witness moderate growth during the forecast period.

Source: Primary Research, Secondary Research, _Market Research Future_ Database and Analyst Review

## **Anti-infective Agent Market Key Players and Competitive Insights**

Major players in the Anti-infective Agent Market are continuously looking for opportunities to enhance their market position. The competitive landscape of the Anti-infective Agent Market is expected to remain highly competitive in the coming years.

Leading Anti-infective Agent Market players are focusing on developing new products and expanding their global presence to gain a competitive edge. They are also investing in research and development to launch innovative and effective anti-infective agents.

Partnerships and collaborations between different companies are another key strategy adopted by players to strengthen their position in the Anti-infective Agent Market. Companies are also focusing on strategic acquisitions to expand their product portfolio and enter new markets.

Other strategies employed by Anti-infective Agent Market development include mergers, joint ventures, and licensing agreements. The competitive landscape of the Anti-infective Agent Market is expected to intensify further in the future, with new entrants and existing players vying for market share.

Pfizer, a leading player in the Anti-infective Agent Market, is committed to providing innovative and effective treatments for patients around the world. The company has a strong portfolio of anti-infective agents, including antibiotics, antifungals, and antivirals.

Pfizer is also actively involved in research and development to discover and develop new anti-infective agents. The company has a global presence and is working to make its products accessible to patients in all corners of the world. Pfizer is committed to being a leader in the fight against infectious diseases and is dedicated to providing high-quality, affordable medicines to patients in need.

Merck, a competitor company in the Anti-infective Agent Market, is also a leading player in the pharmaceutical industry. The company has a strong focus on research and development and is dedicated to discovering and developing new and innovative treatments for infectious diseases.

Merck has a broad portfolio of anti-infective agents, including antibiotics, antifungals, and antivirals. The company is also actively involved in partnerships and collaborations to accelerate the development and delivery of new anti-infective agents to patients.

Merck is committed to providing high-quality, affordable medicines to patients around the world, and is working to make its products accessible to all who need them.

### **Key Companies in the Anti-infective Agent Market Include**

- AbbVie Inc.
- GlaxoSmithKline plc
- Sanofi Pasteur
- Merck Co., Inc.
- [**Pfizer Inc.**](https://www.pfizer.com/science/focus-areas/anti-infectives)
- Roche Holding Ltd
- Bayer AG
- Abbott Laboratories
- BristolMyers Squibb Company
- Eli Lilly and Company
- Amgen Inc.
- Novartis International AG
- Johnson Johnson
- AstraZeneca Plc

## Anti Infective Agent Market Industry Developments

- **Q2 2024: Gilead Sciences Announces FDA Approval of Sunlenca® (lenacapavir) for HIV-1 Infection in Heavily Treatment-Experienced People With Multidrug-Resistant HIV** Gilead Sciences received FDA approval for Sunlenca® (lenacapavir), a new long-acting injectable anti-infective agent for the treatment of HIV-1 infection in adults with multidrug-resistant HIV, marking a significant regulatory milestone for the company.
- **Q2 2024: Pfizer Receives European Commission Approval for Zavicefta® (ceftazidime-avibactam) for the Treatment of Hospital-Acquired Pneumonia** Pfizer announced that the European Commission approved Zavicefta® for the treatment of hospital-acquired pneumonia, expanding the label of this anti-infective agent in the European market.
- **Q2 2024: GSK Announces Positive CHMP Opinion for Gepotidacin, a First-in-Class Oral Antibiotic for Uncomplicated Urinary Tract Infections** GSK received a positive opinion from the European Medicines Agency’s CHMP for gepotidacin, a novel oral antibiotic, moving the drug closer to regulatory approval in Europe.
- **Q1 2024: Shionogi’s Fetroja® (cefiderocol) Receives FDA Approval for Expanded Use in Bloodstream Infections** Shionogi announced that the FDA approved an expanded indication for Fetroja® (cefiderocol), allowing its use in treating bloodstream infections caused by Gram-negative bacteria.
- **Q2 2024: Sandoz Completes Acquisition of GSK’s Cephalosporin Antibiotics Business** Sandoz finalized its acquisition of GSK’s cephalosporin antibiotics portfolio, strengthening its position in the global anti-infective agent market.
- **Q1 2024: BioVersys Raises €20 Million in Series C Financing to Advance Novel Anti-Infective Therapies** BioVersys secured €20 million in Series C funding to support the clinical development of its pipeline of novel anti-infective agents targeting multidrug-resistant bacterial infections.
- **Q2 2024: Venatorx Pharmaceuticals Announces FDA Priority Review for Cefepime-Taniborbactam NDA** Venatorx Pharmaceuticals received FDA priority review for its New Drug Application for cefepime-taniborbactam, a new anti-infective agent targeting multidrug-resistant Gram-negative infections.
- **Q1 2024: Entasis Therapeutics Announces BARDA Contract for Development of Sulbactam-Durlobactam** Entasis Therapeutics was awarded a contract by the U.S. Biomedical Advanced Research and Development Authority (BARDA) to support the development of sulbactam-durlobactam, an anti-infective agent for drug-resistant Acinetobacter infections.
- **Q2 2024: Pfizer and BioNTech Announce New Partnership to Develop mRNA-Based Anti-Infective Vaccines** Pfizer and BioNTech entered into a partnership to co-develop mRNA-based vaccines targeting infectious diseases beyond COVID-19, expanding their collaboration in the anti-infective space.
- **Q1 2024: GSK Opens New Antibiotics Manufacturing Facility in Singapore** GSK inaugurated a new manufacturing facility in Singapore dedicated to the production of antibiotics, enhancing its global supply capabilities for anti-infective agents.
- **Q2 2024: Abbott Receives CE Mark for New Rapid Molecular Test for Respiratory Infections** Abbott received CE Mark approval for its new rapid molecular diagnostic test for respiratory infections, expanding its portfolio of anti-infective diagnostic solutions in Europe.
- **Q2 2024: F2G Secures $70 Million in Series B Funding to Advance Antifungal Drug Development** F2G raised $70 million in Series B financing to accelerate the development of its novel antifungal agents for the treatment of invasive fungal infections.

## **Anti-infective Agent Market Segmentation Insights**

### **Anti-infective Agent Market Product Type Outlook**

- Antibiotics
- Antivirals
- Antifungals
- Antiparasitics
- Others

### **Anti-infective Agent Market Application Outlook**

- Hospital
- Clinic
- Pharmacy
- Home Healthcare
- Others

### **Anti-infective Agent Market End User Outlook**

- Individuals
- Hospitals
- Clinics
- Pharmacies
- Others

### **Anti-infective Agent Market Regional Outlook**

- North America
- Europe
- South America
- Asia Pacific
- Middle East and Africa

## Market Drivers

### 传染病发病率上升

传染病的日益普遍是抗感染药物市场的主要驱动力。随着人口增长和城市化扩展，疫情爆发的风险上升，迫切需要有效的抗感染药物。根据最近的数据，传染病的发生率激增，呼吸道感染和胃肠道疾病居于首位。这一趋势促使医疗系统投资于抗感染药物，从而推动市场增长。随着医疗提供者寻求减轻这些疾病的影响，对创新治疗和预防措施的需求可能会加剧。因此，制药公司正专注于开发新的抗感染药物以应对这一紧迫需求，表明市场潜力强劲。

### 新药批准的监管支持

监管机构越来越多地支持新抗感染药物的批准，这是抗感染药物市场的重要驱动力。旨在加快新疗法审查过程的举措鼓励制药公司投资于研发。例如，提供快速通道认证和优先审查券的项目正在激励急需抗感染药物的开发。这种监管环境促进了创新，并鼓励新疗法的市场推出。因此，行业可能会经历一波新产品的推出，以满足未满足的医疗需求，从而促进市场增长。

### 医疗基础设施投资上升

医疗基础设施的投资不断增加，正对抗感染药物市场产生积极影响。各国政府和私营部门正在投入大量资源，以改善医疗设施，特别是在发展中地区。这项投资旨在改善对基本药物的获取，包括抗感染药物。随着医疗系统的扩展和现代化，对有效治疗的需求预计将上升。此外，改善的医疗基础设施促进了更好的疾病监测和应对能力，进一步推动了对创新抗感染解决方案的需求。这一趋势表明市场增长的有利环境，因为增强的基础设施支持抗感染药物的分发和可及性。

### 药物开发中的技术进步

药物开发中的技术创新正在显著影响抗感染药物市场。先进生物技术方法的出现，如CRISPR和高通量筛选，简化了新抗感染药物的发现和开发。这些技术使研究人员能够更高效地识别潜在的药物候选者，从而减少将新治疗方法推向市场所需的时间和成本。此外，人工智能在药物设计中的整合正在提高针对病原体的精准度。因此，市场上出现了越来越多的新型抗感染药物，这些药物更有效且副作用更少。这一趋势预示着该行业的美好未来，因为创新的步伐持续加快。

### 对抗生素管理的日益关注

对抗感染药物市场的抗生素管理意识日益增强。医疗专业人员和组织认识到负责任使用抗生素以对抗耐药性的重要性。这种意识推动了对替代抗感染药物的需求，包括那些源自天然和新型合成化合物的药物。因此，制药公司正在投资研发，以创造符合管理原则的药物。市场可能会出现向对抗耐药菌株有效且最小化进一步耐药性发展的药物转变。这一不断发展的格局表明，抗感染领域对创新解决方案的迫切需求。

## Future Outlook

抗感染药物市场预计将在2024年至2035年间以4.82%的年均增长率增长，推动因素包括抗生素耐药性上升、医疗支出增加以及技术进步。

**New opportunities:**

- 个性化抗感染疗法的发展

到2035年，市场预计将实现强劲增长，反映出不断变化的医疗需求。

## Segment Insights

### 按类型：抗生素（最大）与抗病毒药物（增长最快）

在抗感染药物市场中，抗生素因其在治疗细菌感染中的广泛使用而占据最大的市场份额。它们作为许多传染病的第一道防线，主导了这一细分市场，对医疗结果产生了显著影响。尽管抗病毒药物目前的市场份额较小，但由于应对病毒感染的日益普遍、研究的增加以及开发有效抗病毒治疗的技术进步，它们正在迅速获得关注。

抗生素（主导）与抗病毒药物（新兴）

抗生素已被确立为抗感染药物市场的主导类别，具有广泛的应用于全球医疗系统。它们对细菌病原体的有效性使其在治疗感染中不可或缺。然而，随着对抗生素耐药性日益关注，该领域正在发展，迫切需要新的策略和创新。另一方面，抗病毒药物代表了一个新兴类别，受到流感和COVID-19等疾病发生率上升的推动。这一增长得益于对新抗病毒药物和疗法的持续研究，强调了公共卫生中有效抗病毒解决方案的需求，从而使抗病毒药物成为未来市场发展的焦点。

### 按应用：医院（最大）与家庭医疗保健（增长最快）

在抗感染药物市场中，应用细分的分布突显出医院作为主要使用场所，占据了最大的市场份额。医院已成为这些药物管理的中心，因为它们能够满足多种感染的需求，服务于多样化的人群，拥有先进的医疗设施和专业知识。相对而言，诊所、药店和居家医疗等细分市场也很重要，但与医院相比，它们通常占据较小的市场份额。

该细分市场的增长趋势显示出对抗感染药物的需求不断增加，推动因素包括传染病的流行率上升和老年人口的增长。值得注意的是，居家医疗部门已成为增长最快的应用细分市场，受到患者偏好向居家接受护理和远程医疗创新的推动。这一趋势表明，门诊治疗可能会重新兴起，利用居家护理服务作为有效管理感染的重点。

医院（主导）与家庭医疗（新兴）

在抗感染药物市场中，医院作为主要应用领域发挥着主导作用，这主要得益于它们处理严重感染的能力以及专业治疗。医院拥有丰富的医疗资源、先进的诊断工具和住院护理设施，使其成为施行抗感染治疗的关键中心。相比之下，居家医疗领域正在迅速崛起，成为一种替代模式，吸引希望在家中接受治疗的患者，享受便利和舒适。这一转变得到了技术创新的支持，使得居家患者监测和远程医疗服务成为可能，从而更容易管理感染，而无需前往医院。随着医疗环境的演变，这两个领域将继续塑造感染管理和治疗的未来。

### 按最终用户：医院（最大）与诊所（增长最快）

在抗感染药物市场中，用户细分分布显示医院主导市场，占据了显著份额，因为它们在管理复杂感染时广泛使用抗感染药物。尽管诊所的市场份额相较于医院较小，但在门诊环境中对可负担治疗的可及性至关重要，需求正在迅速增长。这一趋势突显了医疗服务交付的变化，因为患者越来越倾向于在更本地化的设施中接受护理。

推动这些细分市场的动态是多方面的。医院的基础设施和强大的供应链使其能够有效利用各种抗感染药物。相反，诊所则受益于远程医疗的兴起和对预防性医疗的关注，从而提高了可及性和患者参与度。这一趋势表明，随着患者寻求便利的选择，医疗服务正朝着去中心化的方向发展，进一步推动了临床环境中对抗感染药物的需求。

医院：主导与诊所：新兴

医院在抗感染药物市场中发挥着主导作用，具有全面的治疗能力和广泛的病人护理设施。它们通常配备先进的诊断和治疗技术，这有助于对严重感染的抗感染药物开处方率高。医院对感染控制的关注凸显了它们在有效对抗医院获得性感染时对这些药物的主要依赖。相比之下，诊所代表了一个新兴的细分市场，随着医疗保健向初级护理管理的转变而迅速增长。它们通常提供针对广泛患者人群的抗感染治疗，强调经济实惠和可及性。这一新兴需求与医疗保健趋势相一致，倾向于及时治疗轻微感染和预防性护理措施，使诊所成为抗感染药物分发中日益重要的参与者。

## Regional Market Share Analysis

抗感染药物市场规模在2023年估计为509亿美元，预计到2032年将达到773.7亿美元，2025年至2034年期间的年均增长率为4.8%。从区域来看，北美预计在2023年将占据38.5%的最大市场份额。

这归因于该地区大量制药公司的存在、完善的医疗基础设施以及高额的医疗支出。欧洲预计将成为第二大市场，2023年市场份额为31.2%。

传染病的日益普遍以及对有效抗感染药物的需求增长正在推动该地区市场的增长。

亚太地区预计将成为增长最快的地区，2025年至2034年期间的年均增长率为5.5%。这一增长归因于医疗支出的增加、人口的增长以及对传染病的认识提高。南美和中东及非洲地区预计在预测期内将经历适度增长。

来源：初步研究、二次研究、_市场研究未来_数据库及分析师评审

## Competitive Benchmarking

抗感染药物市场的主要参与者不断寻求机会以增强其市场地位。预计抗感染药物市场的竞争格局在未来几年将保持高度竞争。

领先的抗感染药物市场参与者专注于开发新产品并扩大其全球影响力，以获得竞争优势。他们还在研究和开发方面进行投资，以推出创新和有效的抗感染药物。

不同公司之间的合作与伙伴关系是参与者加强其在抗感染药物市场地位的另一项关键策略。公司还专注于战略收购，以扩展其产品组合并进入新市场。

抗感染药物市场发展的其他策略包括合并、合资企业和许可协议。预计抗感染药物市场的竞争格局在未来将进一步加剧，新进入者和现有参与者争夺市场份额。

辉瑞公司是抗感染药物市场的领先参与者，致力于为全球患者提供创新和有效的治疗。该公司拥有强大的抗感染药物组合，包括抗生素、抗真菌药和抗病毒药。

辉瑞还积极参与研究和开发，以发现和开发新的抗感染药物。该公司在全球范围内开展业务，努力使其产品能够被世界各地的患者所获得。辉瑞致力于在抗击传染病方面成为领导者，并致力于为有需要的患者提供高质量、可负担的药物。

默克公司是抗感染药物市场的竞争对手，也是制药行业的领先参与者。该公司专注于研究和开发，致力于发现和开发新的创新治疗方案以应对传染病。

默克拥有广泛的抗感染药物组合，包括抗生素、抗真菌药和抗病毒药。该公司还积极参与合作与伙伴关系，以加速新抗感染药物的开发和交付。

默克致力于为全球患者提供高质量、可负担的药物，并努力使其产品能够被所有需要的人所获得。

## Recent News & Developments

- **2024年第二季度：吉利德科学公司宣布Sunlenca®（lenacapavir）获得FDA批准，用于治疗重度耐药HIV感染的患者** 吉利德科学公司获得FDA批准，推出Sunlenca®（lenacapavir），这是一种用于治疗重度耐药HIV感染成人的新型长效注射抗感染药物，标志着公司在监管方面的重要里程碑。
- **2024年第二季度：辉瑞公司获得欧洲委员会批准Zavicefta®（ceftazidime-avibactam）用于治疗医院获得性肺炎** 辉瑞公司宣布，欧洲委员会批准Zavicefta®用于治疗医院获得性肺炎，扩大了该抗感染药物在欧洲市场的适应症。
- **2024年第二季度：葛兰素史克公司宣布Gepotidacin的积极CHMP意见，这是一种用于治疗简单尿路感染的首创口服抗生素** 葛兰素史克公司获得欧洲药品管理局CHMP对gepotidacin的积极意见，使该药物更接近于在欧洲的监管批准。
- **2024年第一季度：志昂公司Fetroja®（cefiderocol）获得FDA批准，扩大用于治疗血流感染的适应症** 志昂公司宣布，FDA批准Fetroja®（cefiderocol）扩大适应症，允许其用于治疗由革兰阴性细菌引起的血流感染。
- **2024年第二季度：Sandoz完成对葛兰素史克公司头孢菌素抗生素业务的收购** Sandoz完成了对葛兰素史克公司头孢菌素抗生素产品组合的收购，增强了其在全球抗感染药物市场的地位。
- **2024年第一季度：BioVersys公司在C轮融资中筹集2000万欧元，以推进新型抗感染疗法的发展** BioVersys公司获得2000万欧元的C轮融资，以支持其针对多重耐药细菌感染的新型抗感染药物的临床开发。
- **2024年第二季度：Venatorx制药公司宣布其Cefepime-Taniborbactam新药申请获得FDA优先审查** Venatorx制药公司获得FDA对其Cefepime-Taniborbactam新药申请的优先审查，这是针对多重耐药革兰阴性感染的新型抗感染药物。
- **2024年第一季度：Entasis Therapeutics公司宣布获得BARDA合同，以支持Sulbactam-Durlobactam的开发** Entasis Therapeutics公司获得美国生物医学先进研究与开发局（BARDA）合同，以支持Sulbactam-Durlobactam的开发，这是一种针对耐药性阿西奈特菌感染的抗感染药物。
- **2024年第二季度：辉瑞与BioNTech宣布新合作伙伴关系，共同开发基于mRNA的抗感染疫苗** 辉瑞与BioNTech达成合作，共同开发针对COVID-19以外传染病的基于mRNA的疫苗，扩大了他们在抗感染领域的合作。
- **2024年第一季度：葛兰素史克在新加坡开设新的抗生素生产设施** 葛兰素史克在新加坡启用了一座新的抗生素生产设施，增强了其全球抗感染药物的供应能力。
- **2024年第二季度：雅培公司获得CE标志，用于新的快速分子检测呼吸道感染的测试** 雅培公司获得CE标志，批准其新的快速分子诊断测试，用于呼吸道感染，扩大了其在欧洲的抗感染诊断解决方案组合。
- **2024年第二季度：F2G公司在B轮融资中筹集7000万美元，以推进抗真菌药物的开发** F2G公司在B轮融资中筹集7000万美元，以加速其新型抗真菌药物的开发，治疗侵袭性真菌感染。

## Report Scope

| 2024年市场规模 | 59.96（十亿美元） |
| --- | --- |
| 2025年市场规模 | 62.85（十亿美元） |
| 2035年市场规模 | 100.66（十亿美元） |
| 年复合增长率（CAGR） | 4.82%（2024 - 2035） |
| 报告覆盖范围 | 收入预测、竞争格局、增长因素和趋势 |
| 基准年 | 2024 |
| 市场预测期 | 2025 - 2035 |
| 历史数据 | 2019 - 2024 |
| 市场预测单位 | 十亿美元 |
| 主要公司简介 | 市场分析进行中 |
| 覆盖的细分市场 | 市场细分分析进行中 |
| 主要市场机会 | 个性化医疗的进步提高了抗感染药物市场的疗效。 |
| 主要市场动态 | 抗生素耐药性上升推动了抗感染药物市场的创新和监管审查。 |
| 覆盖的国家 | 北美、欧洲、亚太、南美、中东和非洲 |

## Frequently Asked Questions

**Q: 截至2024年，抗感染药物市场的当前估值是多少？**
A: 抗感染药物市场在2024年的估值为599.6亿美元。

**Q: 2035年抗感染药物市场的预计市场规模是多少？**
A: 预计到2035年，市场将达到1006.6亿美元。

**Q: 在2025年至2035年的预测期内，抗感染剂市场的预期CAGR是多少？**
A: 2025年至2035年期间，市场的预期CAGR为4.82%。

**Q: 在抗感染药物市场中，哪些公司是关键参与者？**
A: 主要参与者包括辉瑞、默克公司、强生、诺华、葛兰素史克、阿斯利康、拜耳、艾伯维和赛诺菲。

**Q: 抗感染药物市场的主要细分领域是什么？**
A: 主要细分包括抗生素、抗病毒药物、抗真菌药物、抗寄生虫药物和其他。

**Q: 抗生素部门在2024年产生了多少收入？**
A: 抗生素部门在2024年的收入在250亿到400亿美元之间。

**Q: 2024年抗病毒药物部门的收入范围是多少？**
A: 抗病毒药物部门在2024年的收入范围为150亿至250亿美元。

**Q: 抗感染药物市场涵盖了哪些应用？**
A: 应用包括医院、诊所、药店、居家医疗等。

**Q: 2024年医院应用领域的收入范围是多少？**
A: 医院应用领域在2024年的收入在200亿到320亿美元之间。

**Q: 哪些最终用户参与抗感染剂市场？**
A: 最终用户包括个人、医院、诊所、药店和其他。


---

*This Markdown endpoint is provided for AI systems and LLM crawlers. For the full interactive report visit https://www.marketresearchfuture.com/reports/anti-infective-agent-market-28826*